Financial Gravity Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Financial Gravity Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Hold	0	–	-$46	–	1583
2023 Q2	–	Hold	0	–	–	–	1410
2021 Q1	–	Hold	0	–	–	–	853
2020 Q4	–	Hold	0	–	–	–	614
2020 Q2	–	Sell	-2	Closed	-$586	–	576
2020 Q1	$586	Hold	2	–	–	﹤0.01%	533
2019 Q4	$22K	Hold	2	–	–	0.02%	978
2019 Q3	$1K	Hold	2	–	–	﹤0.01%	1073
2019 Q2	$1K	Hold	2	–	–	﹤0.01%	1094
2019 Q1	$1K	Buy	+2	New	+$1.19K	﹤0.01%	1149
2018 Q3	$12K	Hold	22	–	–	0.01%	551
2018 Q2	$20K	Buy	22 +20	+1,000%	+$23.1K	0.02%	472
2018 Q1	$2K	Buy	+2	New	+$2.58K	﹤0.01%	978

Other funds holding NKTR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Financial Gravity Asset Management's NKTR Position: Q3 2023 in Review

Financial Gravity Asset Management held its Nektar Therapeutics (NKTR) position steady in Q3 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1583.

Financial Gravity Asset Management first reported a position in NKTR in Q1 2018 and has held it in 8 quarters since. The position peaked at $22K in Q4 2019. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2023.

Financial Gravity Asset Management held 0 shares of Nektar Therapeutics worth $0 as of Q3 2023.
Financial Gravity Asset Management left its Nektar Therapeutics share count unchanged in Q3 2023.
Nektar Therapeutics made up ﹤0.01% of Financial Gravity Asset Management's portfolio in Q3 2023, its #1583 holding.
Financial Gravity Asset Management first reported a position in Nektar Therapeutics in Q1 2018 and has held it in 8 quarters since.
Financial Gravity Asset Management's Nektar Therapeutics position peaked at $22K in Q4 2019.
138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2023.

Based on Financial Gravity Asset Management's 13F filing for Q3 2023, filed 16 Nov 2023.